A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
Latest Information Update: 17 Jan 2024
At a glance
- Drugs PTX-COVID19-B (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Providence Therapeutics
- 12 Dec 2023 Results of pooled analysis from CL001 , CL003 , CL006, CL007 and CL309 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 22 Apr 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2021 Results published in the Providence Therapeutics Media Release.